Author Archives: Joseph Thornton MD

STAT ⁦‪@statnews‬⁩ The pharmaceutical industry is still struggling to tackle Alzheimer’s disease. Now, health tech companies are now trying to take a crack at it. buff.ly/3uK6mIa 3/31/22, 7:00 AM

The Biggs article includes the Daily Record Scale which is use in treatment studies. All sources comment the mechanism of RX is specific to the SSRI as opposed to antidepressants and cite a) immediate clinical effect in PMDD b) lack of effect from non-SRI antidepressants. Occasional use of the SSRI (ie symptoms onset ) asContinue reading “Resource articles on RX of PMDD”

Vandenbroucke lab ⁦‪@Vdb_lab‬⁩ Alzheimer’s disease has an alarming increasing prevalence. We urgently need to improve our understanding behind the pathogenesis. In ⁦‪@FrontImmunol‬⁩ we now give a comprehensive overview on how systemic and intestinal inflammatory processes may affect brain pathology. pic.twitter.com/V8FN8ibW9l 3/24/22, 7:03 AM

JAMA Psychiatry ⁦‪@JAMAPsych‬⁩ This systematic review and meta-analysis explored the outcomes and moderators of psychological interventions delivered by nonspecialists for #depression in low- and middle-income countries. ja.ma/355nlMp #globalhealth #mentalhealth 3/24/22, 6:00 PM

https://jamanetwork.com/journals/jama/fullarticle/2790276

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790171?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamanetworkopen&utm_content=wklyforyou&utm_term=032322

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2790186/mccrary_2022_oi_220125_1647286021.96014.pdf mccrary_2022_oi_220125_1647286021.96014.pdf

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2022.3580?guestAccessKey=385b2eae-ea0b-4259-8314-83a546fae378&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=032122

Joseph (Joe) E. Thornton, M.D., DFAPA